Loading stock data…
$37.86+0.83 (+2.24%)
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
Harmony Biosciences Holdings, Inc. in the Healthcare sector is trading at $37.86 with a market capitalization of $2.4B. Wall Street consensus targets $47.64 (11 analysts), implying a +25.8% move over the next 12 months. The stock is currently 13% below its 52-week high of $43.49, remaining 9.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $261.28M↑ | $215.39M↓ | $243.78M↑ | $239.46M↑ | $200.49M |
| Gross Profit | $198.08M↑ | $170.88M↓ | $175.23M↓ | $179.81M↑ | $162.34M |
| Operating Income | $89.32M↑ | $37.29M↓ | $38.56M↓ | $65.49M↑ | $48.18M |
| Net Income | $75.43M↑ | $32.49M↑ | $22.49M↓ | $50.87M↑ | $39.78M |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule wi...